Sunshine Biopharma Inc (SBFM)

[Norton1973]

SBFM, New's/PR..http://ih.advfn.com/p.php?pid=nmona&article=61651509&symbol=SBFM

Cancer Is on the Rise

"We are alarmed and impassioned by these trends to move vigorously ahead with our clinical development of Adva-27a for aggressive forms of cancer," said Dr. Steve N. Slilaty, Chief Executive Officer of Sunshine Biopharma. "The Company is planning a Phase I clinical trial of Adva-27a for pancreatic cancer in parallel to the Phase I clinical trial of Adva-27a for multidrug resistant breast cancer to be conducted at McGill University's Jewish General Hospital in Montreal (Canada)."

Sunshine Biopharma recently reported that it has initiated the construction of mouse xenograft models for pancreatic cancer as part of the plans of positioning Adva-27a for clinical development for pancreatic cancer in parallel with multidrug resistant breast cancer. Adva-27a is Sunshine Biopharma's lead anticancer compound, a small molecule that has recently been shown to be effective at killing multidrug resistant breast cancer cells, small-cell lung cancer cells, uterine sarcoma cells and pancreatic cancer cells (Published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012). Adva-27a is currently in the IND-Enabling stage of development. The original U.S. patent covering Adva-27a was issued on August 7, 2012 under U.S. patent number 8,236,935.